OncoSec Medical Inc (NASDAQ:ONCS) – Equities research analysts at Piper Jaffray Companies lowered their Q2 2020 earnings per share estimates for OncoSec Medical in a report released on Monday, December 16th, Zacks Investment Research reports. Piper Jaffray Companies analyst E. Tenthoff now anticipates that the biotechnology company will post earnings per share of ($0.91) for the quarter, down from their prior estimate of ($0.79). Piper Jaffray Companies also issued estimates for OncoSec Medical’s Q3 2020 earnings at ($0.76) EPS, FY2020 earnings at ($3.39) EPS, Q1 2021 earnings at ($0.81) EPS, Q2 2021 earnings at ($0.86) EPS, Q3 2021 earnings at ($0.88) EPS, Q4 2021 earnings at ($0.93) EPS and FY2021 earnings at ($3.48) EPS.
Several other equities analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of OncoSec Medical from a “sell” rating to a “hold” rating in a research note on Tuesday. Maxim Group set a $6.00 target price on shares of OncoSec Medical and gave the stock a “buy” rating in a research report on Thursday, October 10th.
Shares of ONCS opened at $1.88 on Thursday. The firm’s 50 day moving average is $1.99 and its 200-day moving average is $2.14. The company has a quick ratio of 2.79, a current ratio of 2.79 and a debt-to-equity ratio of 0.04. OncoSec Medical has a 12-month low of $1.60 and a 12-month high of $9.50.
Several institutional investors have recently added to or reduced their stakes in ONCS. Worth Venture Partners LLC purchased a new position in shares of OncoSec Medical in the second quarter worth approximately $99,000. D.A. Davidson & CO. purchased a new position in shares of OncoSec Medical in the third quarter worth approximately $47,000. JPMorgan Chase & Co. purchased a new position in shares of OncoSec Medical in the second quarter worth approximately $46,000. Salzhauer Michael purchased a new position in shares of OncoSec Medical in the third quarter worth approximately $28,000. Finally, Citadel Advisors LLC purchased a new position in shares of OncoSec Medical in the second quarter worth approximately $33,000. 7.17% of the stock is currently owned by institutional investors and hedge funds.
About OncoSec Medical
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.